Tatsuya Yoshida

7.6k total citations
168 papers, 2.5k citations indexed

About

Tatsuya Yoshida is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Tatsuya Yoshida has authored 168 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 107 papers in Oncology, 91 papers in Pulmonary and Respiratory Medicine and 32 papers in Surgery. Recurrent topics in Tatsuya Yoshida's work include Lung Cancer Treatments and Mutations (68 papers), Cancer Immunotherapy and Biomarkers (46 papers) and Lung Cancer Research Studies (44 papers). Tatsuya Yoshida is often cited by papers focused on Lung Cancer Treatments and Mutations (68 papers), Cancer Immunotherapy and Biomarkers (46 papers) and Lung Cancer Research Studies (44 papers). Tatsuya Yoshida collaborates with scholars based in Japan, United States and United Kingdom. Tatsuya Yoshida's co-authors include Haruhiro Inoue, Yuichiro Ohe, Shinsuke Usui, Toyoaki Hida, Yasushi Yatabe, Shin‐ei Kudo, Hitoshi Satodate, Norio Fukami, Yoshitsugu Horio and Junichi Shimizu and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Tatsuya Yoshida

151 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tatsuya Yoshida Japan	23	1.3k	1.3k	556	469	346	168	2.5k
Chang Young Lee South Korea	29	843 0.6×	1.7k 1.3×	616 1.1×	391 0.8×	297 0.9×	124	2.6k
Aaron T. Wild United States	21	1.3k 1.0×	654 0.5×	435 0.8×	315 0.7×	366 1.1×	53	2.0k
Xin‐Zu Chen China	27	940 0.7×	1.5k 1.2×	1.1k 2.1×	339 0.7×	259 0.7×	125	2.6k
Atsuo Takashima Japan	30	1.7k 1.2×	1.5k 1.2×	923 1.7×	388 0.8×	221 0.6×	222	2.9k
Jean‐Pascal Machiels Belgium	29	1.6k 1.2×	1.1k 0.9×	657 1.2×	806 1.7×	482 1.4×	137	3.1k
Paul E. Van Schil Belgium	19	1.2k 0.9×	2.0k 1.5×	436 0.8×	327 0.7×	378 1.1×	68	2.7k
Xue Hou China	26	1.3k 1.0×	1.0k 0.8×	387 0.7×	376 0.8×	317 0.9×	104	2.1k
Min‐Shu Hsieh Taiwan	28	1.1k 0.8×	1.2k 0.9×	640 1.2×	535 1.1×	270 0.8×	125	2.3k
Olivier Dubreuil France	15	932 0.7×	498 0.4×	378 0.7×	310 0.7×	382 1.1×	56	1.6k
Henri Porte France	26	684 0.5×	1.5k 1.1×	787 1.4×	418 0.9×	337 1.0×	77	2.8k

Countries citing papers authored by Tatsuya Yoshida

Since Specialization

Citations

This map shows the geographic impact of Tatsuya Yoshida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tatsuya Yoshida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tatsuya Yoshida more than expected).

Fields of papers citing papers by Tatsuya Yoshida

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tatsuya Yoshida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tatsuya Yoshida. The network helps show where Tatsuya Yoshida may publish in the future.

Co-authorship network of co-authors of Tatsuya Yoshida

This figure shows the co-authorship network connecting the top 25 collaborators of Tatsuya Yoshida. A scholar is included among the top collaborators of Tatsuya Yoshida based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tatsuya Yoshida. Tatsuya Yoshida is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yoshida, Tatsuya, Noriko Motoi, Yuji Matsumoto, et al.. (2025). Schlafen 11 Expression in Patients With Small Cell Lung Cancer and Its Association With Clinical Outcomes. Thoracic Cancer. 16(1). e15529–e15529. 1 indexed citations

Cho, Byoung Chul, J.T.J.N. Hiltermann, Hiroki Izumi, et al.. (2025). 1853MO Efficacy and safety of rilvegostomig, an anti-PD-1/TIGIT bispecific antibody, for checkpoint inhibitor (CPI)-naïve metastatic non-small cell lung cancer (mNSCLC): ARTEMIDE-01. Annals of Oncology. 36. S997–S998.

Shirasawa, Masayuki, Tatsuya Yoshida, Takaji Matsutani, et al.. (2025). Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC. npj Precision Oncology. 9(1). 17–17. 1 indexed citations

Nishinakamura, Hitomi, Takuma Irie, Takeo Naito, et al.. (2025). Coactivation of innate immune suppressive cells induces acquired resistance against combined TLR agonism and PD-1 blockade. Science Translational Medicine. 17(785). eadk3160–eadk3160. 8 indexed citations

Yoshida, Tatsuya, et al.. (2024). EGFR, TP53, and CUL3 Triple Mutation in Non‐Small Cell Lung Cancer and its Potentially Poor Prognosis: A Case Report and Database Analysis. Thoracic Cancer. 16(3). e15523–e15523.

Dowlati, Afshin, Horst-Dieter Hummel, Stéphane Champiat, et al.. (2024). Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update. Journal of Clinical Oncology. 42(29). 3392–3399. 22 indexed citations

Johnson, Melissa L., et al.. (2024). Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations.. Journal of Clinical Oncology. 42(16_suppl). TPS8654–TPS8654. 2 indexed citations

Wu, Yi‐Long, et al.. (2024). Abstract CT284: A phase 3 randomized controlled trial of zongertinib (BI 1810631) compared with standard of care in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer harboring HER2 tyrosine kinase domain mutations: Beamion LUNG-2. Cancer Research. 84(7_Supplement). CT284–CT284.

Tanaka, Tomohiro, Yasushi Goto, Masafumi Horie, et al.. (2023). Whole Exome Sequencing of Thymoma Patients Exhibiting Exceptional Responses to Pemetrexed Monotherapy. Cancers. 15(16). 4018–4018. 2 indexed citations

10.

Yasuhara, Takaaki, Makoto Nishino, Tatsuya Yoshida, et al.. (2023). An ATR-PrimPol pathway confers tolerance to oncogenic KRAS-induced and heterochromatin-associated replication stress. Nature Communications. 14(1). 4991–4991. 21 indexed citations

11.

Kondo, Shunsuke, Noriko Tanabe, Yuki Katsuya, et al.. (2023). Pathogenic Germline Variants in BRCA1/2 and p53 Identified by Real-world Comprehensive Cancer Genome Profiling Tests in Asian Patients. Cancer Research Communications. 3(11). 2302–2311. 3 indexed citations

12.

Tamura, Kenji, Tatsuya Yoshida, Ken Masuda, et al.. (2023). Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases. ESMO Open. 8(4). 101594–101594. 6 indexed citations

13.

Yoshida, Tatsuya, Takashi Kohno, Ken Masuda, et al.. (2022). Liquid biopsy for the detection of resistance mutations to ROS1 and RET inhibitors in non-small lung cancers: A case series study. Respiratory Investigation. 60(6). 852–856. 2 indexed citations

14.

Horinouchi, Hidehito, Tatsuya Yoshida, Ken Masuda, et al.. (2021). Correlation between body mass index and efficacy of anti-PD-1 inhibitor in patients with non-small cell lung cancer. Respiratory Investigation. 60(2). 234–240. 10 indexed citations

15.

Horinouchi, Hidehito, Ken Masuda, Yuki Shinno, et al.. (2021). Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression. Cancer Immunology Immunotherapy. 71(3). 737–746. 6 indexed citations

16.

Shirasawa, Masayuki, Tatsuya Yoshida, Yuji Matsumoto, et al.. (2020). Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer. European Journal of Cancer. 140. 28–36. 15 indexed citations

17.

Murakami, Shuji, Ryota Shibaki, Yuji Matsumoto, et al.. (2020). Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non‐small cell lung cancer treated with anti‐PD‐1 antibody. Thoracic Cancer. 11(12). 3585–3595. 36 indexed citations

18.

Ichikawa, Junya, Tatsuya Yoshida, Ariel Isser, et al.. (2020). Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells. Clinical Cancer Research. 26(13). 3384–3396. 34 indexed citations

19.

Yoshida, Tatsuya, Genichiro Ishii, Kōichi Goto, et al.. (2014). Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation. Clinical Cancer Research. 21(3). 642–651. 102 indexed citations

20.

Yoshida, Tatsuya, Shinsuke Usui, Haruhiro Inoue, & Shin‐ei Kudo. (2004). The Management of Esophageal Cancer with Situs Inversus Totalis by Simultaneous Hand-Assisted Laparoscopic Gastric Mobilization and Thoracoscopic Esophagectomy. Journal of Laparoendoscopic & Advanced Surgical Techniques. 14(6). 384–389. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact